We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biotage Receives its Largest Order to Date
News

Biotage Receives its Largest Order to Date

Biotage Receives its Largest Order to Date
News

Biotage Receives its Largest Order to Date

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biotage Receives its Largest Order to Date "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Biotage has announced that it has received its largest single order to date. It includes 31 instruments and totals approx. 15 MSEK.

The instruments, which originate from the recently acquired company Argonaut, will be used by chemists to enhance the processes used in the development of pharmaceuticals.

"It's encouraging that we have received an order of this magnitude so soon after the acquisition of Argonaut," says Jeff Bork, president and CEO of Biotage AB.

The instruments are designed to enable the scientists to simulate a number of processes under different conditions and to move from laboratory scale to production scale. The ordered instruments will be installed at the customer's plants in the US and Europe during 2005.

"We are seeing an increased interest worldwide in the pharmaceutical industry towards tools that reduce bottlenecks for process development and full-scale production," says David Patteson, president of Biotage, Discovery Chemistry Group.

He adds, "As Medicinal Chemistry accelerates the hit-to-lead process through automation, the emphasis now moves toward getting NCEs into clinical trials."

The instruments included in the order are Advantage Series® 2410 Personal Screening Synthesizers, Advantage Series® 3400 Multi-reactor Process Chemistry Workstations and Endeavor® Parallel Catalyst-screening Instruments.
Advertisement